Literature DB >> 30025760

Cytokines in cerebrospinal fluid of patients with schizophrenia spectrum disorders: New data and an updated meta-analysis.

Juan A Gallego1, Emily A Blanco2, Sehba Husain-Krautter3, E Madeline Fagen3, Paula Moreno-Merino4, Juan A Del Ojo-Jiménez5, Anthony Ahmed2, Thomas L Rothstein6, Todd Lencz7, Anil K Malhotra7.   

Abstract

Few studies have been conducted examining cytokines in cerebrospinal fluid of patients compared to healthy volunteers. The goals of this study were: 1) to report original data detailing cytokine levels in the cerebrospinal fluid (CSF) of 10 patients with a schizophrenia spectrum disorder (SSD) diagnosis and 10 healthy controls and 2) to conduct a meta-analysis of the available data on cytokine levels in the CSF of patients with SSD compared to healthy controls, including our new data. Cytokine concentrations were measured using the Q-plex Human Cytokine Screen array in CSF of 10 patients with SSD and 10 healthy volunteers. For the meta-analysis, an electronic PubMed and Google Scholar search without restrictions was conducted for articles that reported on cytokine levels in CSF in patients with an SSD compared to healthy controls. Our original data revealed statistically significant increases in levels of interleukin-8 (IL-8) and interleukin-1 beta (IL-1β) in the CSF of patients with an SSD compared to healthy volunteers. Our meta-analysis showed statistically significant increases in interleukin-6 (IL-6) and IL-8 in patients compared to healthy volunteers. Effect sizes between treated and untreated patients for IL-6 were of similar magnitude. However, IL-6 levels were higher in early stage schizophrenia patients compared to chronic schizophrenia patients. Studies with larger sample sizes, comprehensive assessments and ideally in the context of a randomized controlled intervention to minimize the impact of confounding factors are needed to fully understand the role of cytokines and inflammatory markers in the pathophysiology and treatment of schizophrenia.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cerebrospinal fluid; Cytokines; Inflammation; Schizophrenia

Mesh:

Substances:

Year:  2018        PMID: 30025760      PMCID: PMC6564675          DOI: 10.1016/j.schres.2018.07.019

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  39 in total

Review 1.  Cerebrospinal fluid analysis: disease-related data patterns and evaluation programs.

Authors:  H Reiber; J B Peter
Journal:  J Neurol Sci       Date:  2001-03-01       Impact factor: 3.181

2.  A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression.

Authors:  D R Goldsmith; M H Rapaport; B J Miller
Journal:  Mol Psychiatry       Date:  2016-02-23       Impact factor: 15.992

3.  Elevated interleukin-6 in schizophrenia

Authors: 
Journal:  Psychiatry Res       Date:  1999-10-11       Impact factor: 3.222

4.  Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects.

Authors:  Brian J Miller; Peter Buckley; Wesley Seabolt; Andrew Mellor; Brian Kirkpatrick
Journal:  Biol Psychiatry       Date:  2011-06-08       Impact factor: 13.382

5.  Maternal infections and subsequent psychosis among offspring.

Authors:  S L Buka; M T Tsuang; E F Torrey; M A Klebanoff; D Bernstein; R H Yolken
Journal:  Arch Gen Psychiatry       Date:  2001-11

6.  Structural brain alterations in schizophrenia following fetal exposure to the inflammatory cytokine interleukin-8.

Authors:  Lauren M Ellman; Raymond F Deicken; Sophia Vinogradov; William S Kremen; John H Poole; David M Kern; Wei Yann Tsai; Catherine A Schaefer; Alan S Brown
Journal:  Schizophr Res       Date:  2010-06-09       Impact factor: 4.939

7.  Prenatal exposure to influenza as a risk factor for adult schizophrenia.

Authors:  F Limosin; F Rouillon; C Payan; J-M Cohen; N Strub
Journal:  Acta Psychiatr Scand       Date:  2003-05       Impact factor: 6.392

8.  Lower serum cytokine levels in smokers than nonsmokers with chronic schizophrenia on long-term treatment with antipsychotics.

Authors:  Xiang Yang Zhang; Lian Yuan Cao; Cai Song; Gui Ying Wu; Da Chun Chen; Ling Yan Qi; Fan Wang; Mei Hong Xiu; Song Chen; Yingyang Zhang; Lin Lu; Therese A Kosten; Thomas R Kosten
Journal:  Psychopharmacology (Berl)       Date:  2008-08-22       Impact factor: 4.530

9.  The reelin and GAD67 promoters are activated by epigenetic drugs that facilitate the disruption of local repressor complexes.

Authors:  Marija Kundakovic; Ying Chen; Alessandro Guidotti; Dennis R Grayson
Journal:  Mol Pharmacol       Date:  2008-11-24       Impact factor: 4.436

10.  Activation of brain interleukin-1beta in schizophrenia.

Authors:  J Söderlund; J Schröder; C Nordin; M Samuelsson; L Walther-Jallow; H Karlsson; S Erhardt; G Engberg
Journal:  Mol Psychiatry       Date:  2009-12       Impact factor: 15.992

View more
  21 in total

Review 1.  Potential application of helminth therapy for resolution of neuroinflammation in neuropsychiatric disorders.

Authors:  Amir Abdoli; Hoda Mirzaian Ardakani
Journal:  Metab Brain Dis       Date:  2019-07-27       Impact factor: 3.584

Review 2.  Opportunities in precision psychiatry using PET neuroimaging in psychosis.

Authors:  Jennifer M Coughlin; Andrew G Horti; Martin G Pomper
Journal:  Neurobiol Dis       Date:  2019-03-20       Impact factor: 5.996

Review 3.  Recent Reports on Redox Stress-Induced Mitochondrial DNA Variations, Neuroglial Interactions, and NMDA Receptor System in Pathophysiology of Schizophrenia.

Authors:  Narasimha M Beeraka; Marco F Avila-Rodriguez; Gjumrakch Aliev
Journal:  Mol Neurobiol       Date:  2022-01-27       Impact factor: 5.590

Review 4.  The origin of NMDA receptor hypofunction in schizophrenia.

Authors:  Kazu Nakazawa; Kiran Sapkota
Journal:  Pharmacol Ther       Date:  2019-10-16       Impact factor: 12.310

5.  Disruption of the blood-brain barrier in 22q11.2 deletion syndrome.

Authors:  Alexis M Crockett; Sean K Ryan; Adriana Hernandez Vásquez; Caroline Canning; Nickole Kanyuch; Hania Kebir; Guadalupe Ceja; James Gesualdi; Elaine Zackai; Donna McDonald-McGinn; Angela Viaene; Richa Kapoor; Naïl Benallegue; Raquel Gur; Stewart A Anderson; Jorge I Alvarez
Journal:  Brain       Date:  2021-06-22       Impact factor: 13.501

Review 6.  Roles of inflammation in intrinsic pathophysiology and antipsychotic drug-induced metabolic disturbances of schizophrenia.

Authors:  Tyler R Prestwood; Roshanak Asgariroozbehani; Sally Wu; Sri Mahavir Agarwal; Ryan W Logan; Jacob S Ballon; Margaret K Hahn; Zachary Freyberg
Journal:  Behav Brain Res       Date:  2021-01-14       Impact factor: 3.332

Review 7.  Insights into the Pathophysiology of Psychiatric Symptoms in Central Nervous System Disorders: Implications for Early and Differential Diagnosis.

Authors:  Giulia Menculini; Elena Chipi; Federico Paolini Paoletti; Lorenzo Gaetani; Pasquale Nigro; Simone Simoni; Andrea Mancini; Nicola Tambasco; Massimiliano Di Filippo; Alfonso Tortorella; Lucilla Parnetti
Journal:  Int J Mol Sci       Date:  2021-04-23       Impact factor: 5.923

8.  Peripheral immune markers and antipsychotic non-response in psychosis.

Authors:  Daniela Enache; Naghmeh Nikkheslat; Dina Fathalla; B Paul Morgan; Shôn Lewis; Richard Drake; Bill Deakin; James Walters; Stephen M Lawrie; Alice Egerton; James H MacCabe; Valeria Mondelli
Journal:  Schizophr Res       Date:  2021-03-02       Impact factor: 4.662

Review 9.  Neuroimaging Biomarkers in Schizophrenia.

Authors:  Nina V Kraguljac; William M McDonald; Alik S Widge; Carolyn I Rodriguez; Mauricio Tohen; Charles B Nemeroff
Journal:  Am J Psychiatry       Date:  2021-01-05       Impact factor: 19.242

10.  Prednisolone versus placebo addition in the treatment of patients with recent-onset psychotic disorder: a trial design.

Authors:  Lyliana G Nasib; Iris E Sommer; Inge Winter-van Rossum; Jacqueline de Vries; Shiral S Gangadin; Priscilla P Oomen; Gurmeet Judge; Renske E Blom; Jurjen J Luykx; Nico J M van Beveren; Natalie D Veen; Rune A Kroken; Erik L Johnsen
Journal:  Trials       Date:  2020-06-08       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.